EDIT vs TXN · rev $32.3M vs P/E 52, rev $17.68B
Editas Medicine Inc (EDIT) versus Texas Instruments Incorporated (TXN) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Texas Instruments Incorporated (TXN) is a semiconductors company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported TXN revenue for 2025-12-31 was $17.68B. Net income was $5.00B. Revenue was up 13.0% from 2024-12-31 to 2025-12-31. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
EDIT currently screens at market cap $375.2M. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
Not investment advice. Open the EDIT and TXN stock pages for the full models.
Not investment advice.